Key facts
- It has raised $2.5M across 1 recorded rounds; the latest was Seed Round ($2.1M) in Mar 2025.
- Notable investors include Service Provider Capital, Range Ventures, DYDX.
- Cime Therapeutics has filed 1 Form D with the SEC, most recently Mar 2025 ($2.1M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cime Therapeutics
Funding rounds
1 roundsAbout Cime Therapeutics
Developer of an advanced drug discovery company designed to target complex and previously intractable diseases. The company utilizes synthetic chemistry, molecule engineering, and rapid screening techniques, enabling pharmaceutical scientists to effectively uncover therapeutic options, shorten research and development cycles, and deliver treatments that enhance patient care while addressing critical challenges in the field.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2024
- Employees
- 3
- Website
- cimetherapeutics.com/
- Ownership
- Privately Held (backing)
Cime Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cime Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cime Therapeutics in its N-PORT filings yet. We sweep new filings monthly.